3 recruiting, 2 terminated. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Terminated 2 |
| Phase 1 | 2 | Recruiting 2 |
Follow Anwaar Saeed: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) Retifanlimab, Chemotherapy, 9-ING-41 - Pancreatic Adenocarcinoma | Phase 1 | Recruiting | Anwaar Saeed | 12 | 2025-09-22 | 2026-09-24 |
| Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) Zanzalintinib, Durvalumab, Tremelimumab - Hepatocellular Carcinoma | Phase 2 | Recruiting | Anwaar Saeed | 40 | 2024-12-18 | 2025-11-06 |
| Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer Regorafenib, Pembrolizumab - MSI-H Colorectal Cancer | Phase 2 | Terminated | Anwaar Saeed | 1 | 2024-06-26 | 2026-01-20 |
| 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma 9-ING-41, Retifanlimab, Gemcitabine - Pancreatic Adenocarcinoma | Phase 2 | Terminated | Anwaar Saeed | 7 | 2022-01-26 | 2025-07-17 |
| Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies Cabozantinib, Durvalumab, Tremelimumab - Gastric Cancer, Esophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Anwaar Saeed | 117 | 2018-10-22 | 2026-01-21 |
Carcinoma, Hepatocellular (2) · Adenocarcinoma Of Esophagus (1) · Colorectal Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Stomach Neoplasms (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · durvalumab (2) · tremelimumab (2) · Albumin-Bound Paclitaxel (1) · Drug Therapy (1) · Gemcitabine (1) · cabozantinib (1) · pembrolizumab (1) · regorafenib (1)
United States (5)
Anwaar H Saeed, MD (1) · Anwaar M Saeed, MD (1)